A registrational trial in the patients with second line endometrial cancer.
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
Price : $35 *
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- Sponsors PharmaMar
- 09 Nov 2017 New trial record
- 04 Nov 2017 According to a PharmaMar media release, this trial is expected to begin in 2018.